Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Howard Lipkin

Dermatology Brighton, MI Doctor of Osteopathy

NPI 1326130592 CMS profile 60397

2300 Genoa Business Park Dr, Suite 220, Brighton, MI 48114

Open in the dashboard

General payments

$58,114

356 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Howard Lipkin of Brighton, MI is reported in the CMS Open Payments database as having received $58,114 across 356 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $113 5
2024 General $144 1
2023 General $16,186 34
2022 General $26,558 148
2021 General $8,346 95
2020 General $6,076 41
2019 General $691 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Howard Lipkin
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Howard Lipkin were reported at $113. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Howard Lipkin Dermatology median Middle half National median
2019 $691 $454 $129–$1,240 $163
2020 $6,076 $235 $81–$756 $114
2021 $8,346 $377 $108–$1,108 $132
2022 $26,558 $514 $143–$1,391 $149
2023 $16,186 $607 $159–$1,674 $160
2024 $144 $751 $204–$1,903 $164
2025 $113 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $38,161 56 payments
  2. AbbVie, Inc. $16,233 39 payments
  3. Janssen Biotech, Inc. $701 58 payments
  4. Sun Pharmaceutical Industries Inc. $608 38 payments
  5. Galderma Laboratories, L.P. $563 70 payments
  6. Novartis Pharmaceuticals Corporation $239 18 payments
  7. Regeneron Healthcare Solutions, Inc. $233 12 payments
  8. LEO Pharma Inc. $188 10 payments
  9. Pfizer Inc. $183 10 payments
  10. Incyte Corporation $152 7 payments
  11. Other $854 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $48,919 17 payments
  2. Food and Beverage $6,044 323 payments
  3. Travel and Lodging $3,144 15 payments
  4. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. BOTOX $15,378 22 payments
  2. BOTOX COSMETIC $5,815 11 payments
  3. ILUMYA $550 34 payments
  4. SIMPONI ARIA $444 36 payments
  5. STELARA $444 36 payments
  6. REMICADE $444 36 payments
  7. SIMPONI $444 36 payments
  8. AKLIEF $378 50 payments
  9. TREMFYA $257 22 payments
  10. EPIDUO FORTE $216 26 payments
  11. Other $2,819 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

356 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record